GT 2227
Latest Information Update: 03 Feb 2017
Price :
$50 *
At a glance
- Originator Gliatech (CEASED)
- Class Antidepressants; Antihistamines; Neuroprotectants; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder
Most Recent Events
- 02 Feb 2017 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
- 23 Dec 2003 Suspended - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
- 24 Aug 2001 No-Development-Reported for Attention-deficit hyperactivity disorder in USA (Unknown route)